FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Medical Devices

New Pathway for Breakthrough Device Coverage

Centers for Medicare & Medicaid Services (CMS) issues a proposed procedural notice outlining a new Medicare coverage pathway for breakthrough medical ...

latest-news-card-1
Human Drugs

OTC Drug Dispute Resolution Guidance

FDA publishes a draft guidance on the formal dispute resolution and administrative hearing process for over-the-counter monograph drugs.

latest-news-card-1
Federal Register

Medical Imaging Drugs Panel Renewal

Federal Register notice: FDA announces the renewal of the Medical Imaging Drugs Advisory Committee for an additional two years beyond the charter expi...

latest-news-card-1
Medical Devices

Arrow Recalls Peripheral Catheter System

Arrow International recalls its Arrow Endurance Extended Dwell Peripheral Catheter System due to the potential for catheter separation or leakage.

latest-news-card-1
Human Drugs

Indian Drug Companies Sharing Compliance Info

A Bloomberg newsletter covering India reports that Indian drug firms are sharing FDA inspection reports and their responses in an effort to improve in...

latest-news-card-1
Biologics

FDA Accelerated Approval for Duchenne Gene Therapy

FDA grants Sarepta Therapeutics an accelerated approval for its BLA for Elevidys, the first gene therapy for treating pediatric patients aged four thr...

latest-news-card-1
Human Drugs

FDA Posts 483 of PQ Drug Outsourcing Facility

A 10/2022 inspection of drug outsourcing facility PQ Pharmacy of Brooksville, FL leads to a just-posted seven-item Form FDA-483 that cites significant...

latest-news-card-1
Medical Devices

FDA Clears At-home Pulse Baby Monitor

FDA clears an Owlet 510(k) for its BabySat, an at-home pulse-oximetry device for monitoring babies.

Human Drugs

FDA OKs New Colonoscopy Prep

FDA approves Sebelas Suflave colonoscopy prep that reportedly tastes like a sports drink and thus is easier to use.

latest-news-card-1
Human Drugs

Suggestions for Pharmacogenomic Data

Five stakeholders express appreciation for a revised FDA draft guidance on pharmacogenomic data submissions and suggest changes to it.